Nicox SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
NicOx SA Receives Positive Opinion for European Orphan Drug Designation for Naproxcinod for Treatment of Duchenne Muscular Dystrophy
NicOx SA announced that it has received a positive opinion from the European Union Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for naproxcinod, a CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory candidate, for the treatment of Duchenne Muscular Dystrophy (DMD). The orphan drug designation allows companies to benefit from a number of incentives, including a 10-year market exclusivity post-approval, scientific advice and fee reductions. Final approval of the opinion on orphan designation is expected from the European Commission in the coming months. Naproxcinod has shown promising preclinical results in models of muscular dystrophy. Nicox is evaluating the options for developing naproxcinod through a partner as an adjuvant for the treatment of muscular dystrophy or for the treatment of the signs and symptoms of osteoarthritis of the knee. This approach is aimed at maximising the opportunities to progress the development of naproxcinod in one of these indications.
Latest Key Developments in Biotechnology
- Omeros Corp prices $35.0 million public offering of common stock
- Navidea Biopharmaceuticals Inc announces presentation of Lymphoseek three-year recurrence and survival outcomes after Sentinel Lymph Node Biopsy in Patients with Breast Cancer and Melanoma
- Algeta appoints Thomas Ramdahl as new Managing Director
- Algeta ASA appoints chairman; to apply for delisting of shares from Oslo Stock Exchange
- Share this
- Digg this